UNITED STATES  SECURITIES AND EXCHANGE
COMMISSION  WASHINGTON, D.C. 20549  FORM 10-QSB  [X]      
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 For the quarterly period ended September 30, 2006  [
]         TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition
period from __________________ to __________________  Commission File Number 0-23957  MEDITECNIC, INC. (Exact Name of small business
issuer as specified in its charter)  Nevada87-0430532 (State or other Jurisdiction
of                                                                         
I.R.S. Employer Identi- Incorporation or
Organization                                                                                 
fication No.)  24351 Pasto Road, #B, Dana Point, California
92629 (Address of Principal Executive
Offices)                                                                          
(Zip Code)  (949)
489-2400 (Issuer's Telephone Number, including Area Code)  Indicate by check mark whether the Registrant (i) has filed all reports required
to be filed by Section 13, or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (of for such shorter period that the Registrant
was required to file such reports) and (ii) has been subject to such filing
requirements for the past 90 days.  YesNo
X Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Exchange Act. YesNo __X__ Indicate the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date.  Common Stock, par value  $.0017,527,485 Title of
Class                                                                                       
Number of Shares outstanding at October 6, 2008


MEDITECNIC, INC. (A
DEVELOPMENT STAGE COMPANY) BALANCE
SHEET AS OF SEPTEMBER 30, 2006
AND DECEMBER 31, 2005  ASSETSSEPTEMBER
30,              
DECEMBER 31, Current
Assets                                                                                                                          
2006                                 
2005 Cash and cash
equivalents                                                                                     
$            
155,117           
$            
107,781 Interest
Receivable                                                                                                                           
22                                    
-- Accounts
Receivable                                                                                                                     
891                            
19,998 Inventory                                                                                                                                  
103,014                          
103,764 Prepaid
Expenses                                                                                                                       
61,706                                    
-- Marketable
Securities                                                                                               
25,887           
-- Total Current
Assets                                                                                                                       
346,637                          
231,543  Fixed Assets Vehicles                                                                                                                                       
16,921                            
15,774 Office
Furniture                                                                                                                          
22,124                            
17,871 Office
Equipment                                                                                                      
29,211           
48,728 68,256                            
82,373 Accumulated
Depreciation                                                                                      
(53,103)           
(47,319) Total Fixed
Assets                                                                                                                             
15,153                            
35,054  Other Assets Patents                                                                                                                                       
871,326                          
871,326 Research and
Development                                                                                                              
--                          
142,257 Deposits                                                                                                                     
--           
15 Total Other
Assets                                                                                                                          
871,326                       
1,013,598  Total
Assets                                                                                                                      
$         
1,233,116           
$         
1,280,195  LIABILITIES AND STOCKHOLDERS' EQUITY
(DEFICIT) Current Liabilities Accounts
payable                                                                                                    
$            
170,727           
$            
171,166 Deferred
Revenues                                                                                                                            
--                                    
-- Accrued
Payroll
Taxes                                                                                                                
8,034                              
4,795 Other Current
Liabilities                                                                                           
--           
8,093 Total Current
Liabilities                                                                                                                  
178,761                          
184,054  Long Term Liabilities Payable to
Related
Party                                                                                                         
177,942                            
84,081 Loans from
Shareholders                                                                                         
2,032,731           
1,798,856 Total Long Term
Liabilities                                                                                                         
2,210,673                       
1,882,937  Stockholders Equity Preferred
Stock (1,000 shares issued and
outstanding)                                                                
1                                     
1 Capital Stock
(7,527,485 issued and
outstanding)                                                                  
7,528                              
7,528 Additional
Paid In
Capital                                                                                                   
3,495,072                       
3,495,072 Accumulated
Deficit During the Development
Stage                                                  
(4,748,354)                    
(4,379,486) Accumulated
Other Comprehensive
Income                                                        
89,436           
90,090 (1,156,318)                       
(786,796)  Total Liabilities and Stockholders
Equity                                                                    
$         
1,233,116           
$       (1,280,195) (0.29) See
accompanying Notes to Financial Statements.  MEDITECNIC, INC. (A
DEVELOPMENT STAGE COMPANY) STATEMENTS OF
OPERATIONS CUMULATIVE FOR THE
NINE                                      
FOR THE
THREE                     
FROM MONTHS
ENDED                                  
MONTHS ENDED           
MARCH 24, 1998 SEPTEMBER 30       SEPTEMBER
30     SEPTEMBER 30   SEPTEMBER
30           TO 2006                           
2005                         
2006                       
2005           
JUNE 30, 2006 Income Sales
Turnover                                          
$                
--           
$                
--           
$            
--       
$              
--         
$            
258,814 Research and
Development                                        
--                              
--           
              
--                        
--         
              
357,332 Realization of
Patents                                                  
--                              
--                          
--                        
--                          
90,734 Other
Revenues                                        
679           
--           
--       
--         
15,251 Total
Income                                                  
               
679                              
--                          
--                        
--                        
722,131 Operating Expenses Supplies                                                                 
33,771                              
--                  
11,257                        
--                          
33,771 General and
Administrative                                
25,485                      
19,913                    
1,022                  
1,223                        
321,825 Bank
Charges                                                         
1,246                           
881                       
335                     
304                          
52,471 Audit
Fees                                                            
19,810                              
--                    
3,270                        
--                          
98,545 Marketing and
Advertising                                
15,111                        
1,796                    
5,037                  
1,272                          
33,342 Other Financial
Charges                                       
1,191                           
350                           
1                        
--                          
58,766 Legal and
Honoraries                                          
11,397                      
35,187                          
--                  
9,452                        
144,556 Research and
Development                               
17,512                              
--                    
8,333                        
--                     
1,067,356 Translation
Fees                                                           
--                              
--                          
--                        
--                            
3,619 Patent
Fees                                                           
18,897                      
84,563                          
--                  
1,833                        
740,742 Travel                                                          
            
2,508                        
2,108           
           
836                     
721                        
133,405 Depreciation                                              
            
5,784                        
4,885           
        
1,928                  
2,889                          
53,103 Amortization                                              
                  
--                      
36,234           
              
--                
17,393                        
592,347 Staff
Research                                                    
142,233                    
182,266                  
47,411                
63,665                     
1,356,018 Office
Expense                                                        
1,761                        
6,639                       
587                     
651                          
48,976 Vehicle
Expense                                                     
1,530                        
4,767                       
510                  
1,602                          
14,649 Entertainment                                                                
--                              
--                          
--                        
--                          
17,258 Small Materials and
Supplies                                     
--                              
--                          
--                        
--                          
69,490 Postage
Delivery                                       
                  
--                           
176           
              
--                       
40                            
1,943 Insurance                                                                   
999                        
2,893                       
333                  
(508)                          
14,214 Promotions and
Seminars                                     
1,544                        
6,263                       
772                  
6,263                          
97,286 Telephone                                                               
1,053                        
1,641                       
351                     
681                          
18,153 Office
Rent                                                            
44,631                      
47,923                  
14,877                
14,039                        
337,200 Utilities                                                                    
3,227                              
--                    
1,076                        
--                            
3,545 Repairs and
Maintenance                                     
2,266                              
--                    
1,133                        
--                            
4,007 Payroll
Taxes                                             
16,746           
41,254           
5,582       
(8,821)         
132,339 Total Operating
Expenses                                    
368,702                    
479,739                
104,651              
112,699                     
5,448,926  Net Operating Income
(Loss)                      
(368,023)           
(479,739)           
(104,651)       
(112,699)         
(4,726,795) Other Income (Expense) Interest
Income                                         
               
130                              
--           
             
65                        
--                          
38,737 Interest
Expense                                                           
--                              
--                          
--                        
--                       
(38,342) Loss on Disposal of
Assets                                       
--                   
(71,490)                          
--                        
--                       
(14,288) Insurance
Indemnities                                                 
--                              
--                          
--                        
--                          
10,568 Other
taxes                                                 
(975)           
(1,370)           
(325)       
--         
(18,234) Total Other Income
(Expense)                                  
(845)                   
(72,860)                    
(260)                        
--                       
(21,559)  Net Income
(Loss)                                        
$   
(368,868)           
$   
(552,599)           
$ (104,911)        $ 
(112,699)         
$       (4,748,354) Other Comprehensive Income (Loss) Gains (Losses) on Exchange
Rates        
               
651                      
95,567           
           
699                
49,534                          
43,429 Change in Value of Life
Insurance         
                  
--                              
--           
              
--                        
--                          
12,744 Gain (Loss) in Marketable
Securities     
(1,305)           
(6,050)           
(240)       
--         
33,263 Net Other Comprehensive Income (Loss) 
(654)           
89,517           
459       
49,534         
89,436  Net Income (Loss) per
share                       
       
(0.0490)           
$     
(0.0734)           
$  (0.0139)        $   
(0.0150)         
$           
(0.6308)  Weighted Average Number of Shares
Outstanding                 
7,527,485                 
7,527,485         
7,527,485             
7,527,485                         
7,527,485  See
accompanying Notes to Financial Statements.  MEDITECNIC, INC. (A
DEVELOPMENT STAGE COMPANY) STATEMENTS OF CASH
FLOWS CUMULATIVE FOR THE
SIX                                       
FOR THE
THREE                     
FROM MONTHS
ENDED                                  
MONTHS ENDED           
MARCH 24, 1998 SEPTEMBER 30       SEPTEMBER
30     SEPTEMBER 30   SEPTEMBER
30           TO 2006                           
2005                         
2006                       
2005           
JUNE 30, 2006 CASH FLOWS FROM OPERATING ACTIVITIES  Net
Income                                                   
$     
(368,868)         
$     
(552,599)         
$     
(104,911)        $   
(112,699)       
$       (4,748,354)  Adjustments to reconcile net income to net
cash provided by operating activities Depreciation                                                           
5,784                    
105,957                        
1,928                    
2,889                        
53,103 Amortization                                                                 
--                      
54,039                              
--                  
17,393                      
592,347 Increase (decrease) in: Interest
Receivable                                                  
(22)                              
--                              
--                          
--                            
(22) Accounts
Receivable                                          
19,107                     
(7,435)                              
--                          
--                          
(891) Prepaid
Expenses                                              
(61,706)                              
--                              
--                          
--                     
(61,706) Inventory                                                                   
750                        
(544)                              
--                          
--                   
(103,014) Research and
Development                             
128,475                   
(69,343)                              
--                          
--                   
(606,129) Decrease (Increase) in: Accounts
Payable                                                  
(439)                        
2,991                     
(1,168)                 
(4,642)                      
170,727 Accrued Payroll
Taxes                                          
3,239                              
--                              
--                          
--                          
8,034 Deferred
Revenue                                                        
--                      
26,009                              
--             
(108,546)                                
-- Other Comprehensive
Income                              
(654)                      
89,517                        
(459)                  
49,534                        
89,436 Other Current
Liabilities                         
(8,093)         
(526)         
--       
--       
-- Net Cash Provided (Used)
By Operating
Activities                                    
  
(228,427)                 
(351,934)                  
 (103,692)             
(156,071)                
(4,606,470)  CASH FLOWS FROM INVESTING ACTIVITIES Cash Used for
Deposit                                               
15                              
--                              
--                          
--                                
-- Cash Used of Patent
Acquisition                              
--                              
--                              
--                          
--                   
(871,326) Acquisition of Fixed
Assets                                       
--                              
--                              
--                          
--                     
(68,256) Disposal of Fixed
Assets                                    
27,900                        
9,731                              
--                    
6,207                      
13,783 Increase (decrease) in
Marketable Securities                                                
(25,887)         
20,287         
--       
19,331       
(25,887) Net Cash (Used) By
Investing Activities                                                               
2,028                       
30,018                            
  
--                   25,538                 
  (951,686)  CASH FLOWS FROM FINANCING ACTIVITIES Loans From
Shareholders                                 
233,875                    
305,318                    
208,191                
160,431                   
2,032,731 Payable to Related
Party                                     
93,861                              
--                              
--                          
--                      
 177,942 Sale of Common
Stock                           
--         
--         
--       
--        
 3,502,601 Net Cash (Used) By
Financing Activities                                                           
 
322,736                   
305,318                   
 208,191               
160,431               
     5,713,274  NET INCREASE (DECREASE) IN CASH
            
47,336                   
(16,598)                    
104,499                  
29,898                      
155,117 CASH AT BEGINNING OF
PERIOD        
107,781         
91,762         
50,618       
45,266       
-- CASH AT END OF
PERIOD                     
$        
155,117         
$          
75,164         
$        
155,117       
$        
75,164       
$            
155,117  Cash Paid for
Interest                                                      
--                        
1,324                              
--                       
861                        
17,338 See accompanying Notes to Financial
Statements.  MEDITECNIC, INC. (A Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) SEPTEMBER 30, 2005   NOTE A  SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES  A summary of significant accounting policies of Meditecnic, Inc. (Predecessor, Viking Broadcasting Corporation) is presented to assist in understanding the Companys financial statements. The financial statements and notes are representations of the Companys management who are responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the accompanying financial statements.  The accompanying financial statements are unaudited, but in the opinion of the management of the Company, contain all adjustments, consisting of only normal recurring accruals, necessary to present fairly the financial position at September 30, 2005, the results of operations for the three and nine months ended September 30, 2006 and 2005, and the cash flows for the three and nine months ended September 30, 2006 and 2005.  Reference is made to the Company's Form 10-KSB for the year ended December 31, 2005.  The results of operations for the three and nine months ended September 30, 2006 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2006.  Organization, Nature of Business and Trade
Name  Meditecnic, Inc. (The Company) was incorporated in the State of Nevada on March 24, 1998. Meditecnic, Inc. is the successor by merger on April 18, 1998 with Viking Broadcasting Corporation, (Viking) a Utah corporation incorporated on May 1, 1984 as Carrigan Gold Corporation. Viking was originally formed to sell and deal in minerals, oil and gas properties. This venture and an investment in broadcasting properties were unsuccessful. Because of the unsuccessful ventures, prior to the merger and the subsequent acquisition of certain patent rights, Viking was inactive and had discontinued operations.  The Company has acquired the technology related to its
endoscopic applications from Meditecnic, S.A. (Meditecnic), which
also performs research and development for the Company.  The financials include the accounts of Meditecnic, Inc.,
Viking Broadcasting Corporation and Meditecnic, S.A. a wholly owned subsidiary.
On April 18, 1998, Meditecnic, Inc. merged with Viking Broadcasting Corporation
being the surviving company and establishing the surviving entitys name to be Meditecnic, Inc.
The Company's primary business is developing and marketing advanced products for
dental and endoscopic applications.  Prior to April 18, 1998, Meditecnic, Inc. had been a privately owned and operated development stage company. The Company has not generated any significant revenues from its operations and is defined as a development stage company per SFAS No. 7.  Basis of Presentation  The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that effect the reported
amounts of assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during the reported period. Actual
results could differ from those estimates. Management further acknowledges that
it is solely responsible for adopting sound accounting practices, establishing
and maintaining a system of internal accounting control and preventing and
detecting fraud. The Companys system of internal accounting control is   MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS   NOTE A  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)  Basis of Presentation (continued)  designed to assure, among other items, that (1) recorded
transactions are valid; (2) all valid transactions are recorded and (3)
transactions are recorded in the period in a timely manner to produce financial
statements which present fairly the financial condition, results of operations
and cash flows of the company for the respective periods being
presented.  Foreign Currency Translation  Foreign Currency Transactions  (all of which have been in Swiss Francs) are translated into US dollars at the applicable average daily interbank   floating rates of exchange, prevailing at the dates of the transactions.  Monetary assets and liabilities denominated in foreign currencies are translated into US dollars using the applicable exchange rates prevailing at the balance sheet date.  The Company's share capital and reporting currency is denominated in US dollars.  Property and Equipment  Property and equipment are carried at cost. Expenditures
for maintenance and repairs are charged against operations. Renewals and
betterments that materially extend the life of the assets are capitalized. When
assets are retired or otherwise disposed of, the cost and related accumulated
depreciation are removed from the accounts, and any resulting gain or loss is
reflected in income for the period.  Depreciation is computed for financial statement
purposes on a straight-line basis over estimated useful lives of the related
assets. The estimated useful lives of depreciable assets are: Estimated Useful
Lives Office
Equipment                     
5-10 years Office
Furniture                        5-7 
 years Shop
Tools                               
5-7  years Vehicles                                   5-10
years  For federal income tax purposes, depreciation is computed under the modified accelerated cost recovery system. For audit purposes, depreciation is computed under the straight-line method.   MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS   NOTE A  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)  Use of Estimates  The preparation of financial statements in accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.  A change in managements estimates
or assumptions could have a material impact on Meditecnic, Inc.s financial
condition and results of operations during the period in which such changes
occurred. Actual results could differ from those estimates. Meditecnic, Inc.s
financial statements reflect all adjustments that management believes are
necessary for the fair presentation of their financial condition and results of
operations for the periods presented.  Loss Per Share - Basic and Diluted  The Company follows SFAS No. 128, "Earnings Per Share".  Basic earnings per share is computed by dividing income available to common stock holders by the weighted average number of shares outstanding.  In computing diluted earnings per share, the weighted average number of shares outstanding is adjusted to reflect the effect of potentially dilutive securities including options, warrants, preferred stock or contingently issuable (or escrowed) stock, and income available to common stockholders is adjusted to reflect any changes in income or loss that would result from the issuance of the dilutive common shares.  There were no potential common shares included in the calculation of diluted loss per share for the three months  and nine  ended September 30, 2006 and 2005, because the effect would have decreased the loss per share amount and therefore been anti-dilutive.  Cash and Cash Equivalents  For purposes of the statement of cash flows, the Company
considers all short-term debt securities purchased with maturity of three months
or less to be cash equivalents.Cash
equivalents are carried at cost, which approximates market. The Company
maintains cash in bank deposits accounts, which, at times, may exceed federally
insured limits or are in foreign banks.  Revenue and Cost Recognition  The Company reports income and expenses on the accrual
basis of accounting, whereby income is recorded when it is earned and expenses
recorded when they are incurred. In this specific industry revenue is generated
from the sale of approved devices. No devices have been approved to this date;
therefore, no revenue from operations has been generated.     MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  NOTE A  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(continued)  Revenue and Cost Recognition (continued)  Job costs include all direct materials, and labor costs
and those indirect costs related to production of approved medical devices.
Selling, general and administrative costs are charged to expense as
incurred.  Cost of Goods Sold  Job costs include all direct materials, and labor costs
and those indirect costs related to production. Selling, general and
administrative costs are charged to expense as incurred.  Advertising  Expenses related to specific jobs are allocated and
classified as costs of goods sold. Expenses not related to specific jobs are
recorded as general and administrative expenses. Advertising expense for the
nine months  ended September 30, 2006 and 2005totaled $15,111 and
$1,796,  respectively.  Principles of Consolidation  These consolidated financial statements are presented
based on the generally accepted accounting principle of consolidation and
merger. These principles state that a new enterprise is formed through the
exchange of stock, or payment of cash or other property, or the issue of debt
instruments. Consolidated statements are then presented based on the combining
of the results of operations and the financial position of both companies
essentially as if the two were a single entity in the periods
presented.  The consolidated financial statements include the
accounts of Meditecnic, Inc. and Meditecnic, S.A. Intercompany balances have
been eliminated in these consolidated statements.  Stock  The Company has authorized common stock and has also
authorized preferred stock (see Note H).  Recently Issued Accounting Pronouncements  In December of 2002, the FASB issued SFAS 148,
Accounting for Stock-Based Compensation  Transition and Disclosure  An
Amendment of FASB Statement No. 123.  SFAS 148 provides alternative
methods of transition for a voluntary change to the fair value based method of
accounting for stock-based employee compensation.  In addition, the
statement amends the disclosure requirements of Statement No. 123 to require
prominent disclosures in both annual and interim financial statements about the
method of accounting for stock-based employee compensation and the effect of the
method used on reported results.   MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  Recently Issued Accounting Pronouncements
(continued)  In April 2003, the FASB issued SFAS No. 149,
Amendment of Statement 133 on Derivative Instruments and Hedging
Activities SFAS No. 149 amends and clarifies financial accounting and
reporting for derivative instruments, including certain derivative instruments
embedded in other contracts and for hedging activities under FASB Statement No.
133.  Accounting for Derivative Instruments and Hedging
Activities, SFAS No. 149 is generally effective for contracts entered into
or modified after June 30, 2003 and for hedging relationships designated after
June 30, 2003.  In May 2003, the FASB issued SFAS No. 150,
Accounting for Certain Financial Instruments with Characteristics of both
Liabilities and Equity.  SFAS No. 150 establishes standards for how an
issuer measures certain financial instruments with characteristics of both
liabilities and equity and requires that an issuer classify a financial
instrument within its scope as a liability (or asset in some
circumstances).  SFAS No. 150 was effective for financial statements
entered into or modified after May 31, 2003 and otherwise was effective and
adopted by the Company in 2003.  In May 2005, the FASB issued SFAS No. 154,
Accounting Changes and Error Corrections, a replacement of APB Opinion No.
20 and FASB Statement No. 3.  This statement changes the requirements
for the accounting for and reporting of a change in accounting principle. 
Previously, Opinion 20 required that most voluntary changes in accounting
principle be recognized by including in net income of the period of change the
cumulative effect of changing to a new principle.  This statement requires
retrospective application to prior periods financial statements of change sin
accounting principle, when practicable.  None of the above new pronouncements has current
application to the Company, but may be applicable to the Companys future
financial reporting.  NOTE B  ACCOUNTS RECEIVABLE  Accounts receivable is defined as amounts due from
customers for goods and services provided in the normal course of business
operations.  All amounts are based on actual costs incurred.  The receivables that total the amount on the balance
sheet are from invoices issued to long time customers that are considered good
credit risks and have a history of paying invoices within a reasonable length of
time.  Therefore we have determined through analysis of past historical
experience for this Company the allowance for bad debt would be less than one
half of one percent (.5%) of the receivables listed on the books.   MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS   NOTE C  INTEREST RECEIVABLE  Interest receivable is defined as the current value of
interest amounts due on trade receivables and note receivables.  The
interest receivables on these financial statements consist of amounts charged to
customers for financing and accrued on liquid assets.  As of September 30,
2006 and 2005, interest receivables were valued at $0 and $0.  NOTE D - MARKETABLE SECURITIES  The Company's securities investments that are bought and held principally for the purpose of selling them in the near term are classified as trading securities.  Trading securities are recorded at fair value on the balance sheet in current assets, with the change in fair value during the period included in earnings.  Net increase (decrease) in marketable securities for the nine months ended September 30, 2006 was $(25,887)and for 2005 was $20,287.  NOTE E  FIXED ASSETS  Fixed assets consist of vehicles, officer equipment and furniture and organization costs less depreciation.  NOTE F  PREPAID EXPENSES  Prepaid expenses are prepayments made to secure the use of assets or the receipts of services at a future date.  The amounts listed on the financial statements presented as prepaid assets are for insurance contracts that overlap the years presented.  NOTE G  - DEPOSITS  The Company paid CHF 400,000 ($258,550) in September 1999 and January 2000 as a deposit on purchase of Meditecnic, S.A., a non-affiliated research contractor.  As of September 12, 2002 the purchase was completed and Meditecnic, S.A. became a wholly owned subsidiary.   MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  NOTE G  - DEPOSITS (continued)  In addition the Company placed a CHF 60,000 deposit for the purchase of patents in December 2003 ($38,346) and a CHF 100,000 ($60,390) for the purchase of an additional patent in February 2001.  Additional deposits were made in 2000 toward patent purchases in the amount of $159,814.  All deposits have been classified as patent deposits as the patents from Meditecnic, SA were purchased by Meditecnic, Inc., prior to the completion of the stock purchase.  NOTE H  PATENTS  Acquisition costs of patents are capitalized.  The Company acquired certain patents by agreement dated March 24, 1998 for a purchase price of CHF 950,000 ($637,260 at the exchange rate in effect on the contract date).  The Company paid all amounts on the contract by July 30, 1998.  These patents will be amortized commencing on commercialization of the patents. Annual taxes and patent license fees and legal costs associated therewith are expensed as incurred.  The continuing carrying value of patents is assessed based upon the Company's operating experience, expected cash flows from related products and other factors as deemed appropriate.  NOTE I - INCOME TAXES  The Company follows Statement of Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes", which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are         recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts are each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income.  Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.  As of September 30, 2006 and 2005 there were no deferred tax liabilities or assets. As of September 30, 2006, the Company had net operating loss carryforwards for federal purposes of over $150,000. The federal net operating loss carryforward have begun expiring. The utilization of net operating loss carryforwards may be limited under the provisions of Internal Revenue Code Section 382 and similar state provisions.  The Company has no U.S. operations and is incorporated in Nevada, which levies no income tax on corporations.  Due to the inherent uncertainty in forecasts and future events and operating results, the Company has provided for a valuation allowance in an amount equal to gross deferred tax assets resulting in no net deferred tax assets or liabilities for the periods audited.  MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  NOTE J  RESEARCH AND DEVELOPMENT  Research and Development Costs are capitalized on actual costs incurred.  Amortization is calculated on the Net Book Value of the Research and Development item/project, and an amortization rate of 33% (percent) per year.  Other Company sponsored research and development costs related to both present and future products are expensed as incurred.  NOTE K  NOTE RECEIVABLE  Note receivable is comprised on a note in the amount of $3,199,592 loaned in various increments beginning in April 2000 to Meditecnic, S.A., which at the time of the loan agreement was an unaffiliated company.   The Company is now a fully owned subsidiary of Meditecnic, Inc., which performs research and development for the Company.  The note was due on December 31, 2002 and bears interest at 5% per annum, payable semi-annually.  As part of the consolidation process the receivables from Meditecnic, SA and the payables to Meditecnic, Inc. related to this footnote were eliminated.  NOTE L  ACCOUNTS PAYABLE  These accounts represent the actual costs of amounts due to Vendors and Suppliers for goods and services received.  NOTE M  ACCRUED PAYROLL TAXES  These accounts represent the actual amounts of unpaid payroll taxes as of the end of each period.  NOTE N  LONG TERM LIABILITIES/POSTPONED STOCKHOLDERS LOANS  These accounts consist of amounts due to stockholders, on which payments have been postponed.  As of the date of these financial statements, Management at Meditecnic is of the opinion that these amounts can be considered as a loss; only a return to a positive Net Stockholders Equity could liberate the postponed amounts.   MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  NOTE O - FOREIGN CURRENCY TRANSACTION GAIN (LOSS)  Foreign currency transaction gains and losses result from a change in exchange rates between the functional currency of the Company and the currency in which a foreign transaction is denominated.  These gains or losses are comprised of actual currency gains or losses realized upon settlement or foreign currency transactions and expected (unrealized) currency gains or losses on unsettled foreign currency transactions.  NOTE P - STOCKHOLDERS' EQUITY  In March 1998 the Company effected a placement under Rule 504 of Six Million (6,000,000) shares of common stock and One Thousand (1,000) shares of Series A Preferred Stock to ten persons for $101,735 and options to purchase One Million Five Hundred Thousand (1,500,000) shares at $2.00 per share.  The options were exercised in fiscal 1998 for net proceeds of $2,980,821 (net offering costs).  When the Company changed domicile to Nevada, the capital structure was changed to authorize Fifty Million (50,000,000) shares of common stock,, $.001 par value, and Ten Million (10,000,000) shares of preferred stock,  $.001 par value.  One Thousand (1,000) shares of preferred stock have been designed as Class A with the following rights and privileges: - no rights to dividends - no redemption value - liquidation limited to $.01 per share - rights (as a whole) to vote 2/3 (two thirds) of the  members of the  board  of  directors -no  conversion  rights -restrictions on transferability  NOTE Q COMMITMENTS  The Company has signed a contract with an individual to pay CHF 40,000 for the purchase of the technical and intellectual properties related to the Company's dental and endoscopic business.  The contract also calls for his assistance in the further development of the technology as much as possible over and unspecified period of time.  NOTE
R  GOING CONCERN  Under
the going concern assumption, an entity is ordinarily viewed as continuing in
business for the foreseeable future with neither the intention nor the necessity
of liquidation, ceasing trading, or seeking protection from creditors pursuant
to laws or regulations. Accordingly, assets and liabilities are recorded on the
basis that the entity will be able to realize its assets and discharge its
liabilities in the normal course of business.  MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  NOTE
R  GOING CONCERN (continued)  The Company has had limited operations to date other than the acquisition of the patents and license rights.  In March 1998 the Company raised $100,000 in an offering of common stock.  In 2000 the Company sold $3,000,000 in Common Stock. The Company is in the research and development stage of its products.  Research and development costs were $223,598 in fiscal 2001, $230,817 in fiscal 2000 and $206,508 in fiscal 1999.  Research and development was carried out by a (previous to the acquisition) non-affiliated entity, Meditecnic SA, on a contractbasis. The Company exercised its option to purchase all of the capital stock of Meditecnic SA for CHF 400,000 grantedNovember 5, 2001, of which CHF 300,000 ($195,720) was paid in November 2001 and is accounted for on the December 31, 2001 balance sheet as a deposit.  The Company has also loaned funds to Meditecnic SA prior to the exercising of the purchase agreement. In addition the Company placed a CHF 60,000 deposit for the purchase of patents in December 2000 ($38,346) and a CHF 100,000 ($60,390) for the purchase of an additional patent in February 2001.  Due to the exercising of the subsidiary stock purchase the intercompany balances have been eliminated.   NOTE
S - NET LOSS PER COMMON SHARE  Net loss per share is calculated in accordance with SFAS
No. 128, Earnings Per Share. The weighted average number of common shares
outstanding during each period is used to compute basic loss per
share.  Basic net loss per common share is based on the
weighted-average number of share of common stock of Seven Million Five Hundred
Twenty Seven Thousand Four Hundred Eighty Five (7,527,485)
outstanding.  MEDITECNIC, INC., (A Development Stage Company) (Predecessor, Viking Broadcasting Corporation) NOTES TO FINANCIAL STATEMENTS  NOTE T  ACQUISITION  An acquisition of a company occurs when one enterprise
pays cash, or issues stock or debt for all or part of the voting stock of
another enterprise. The acquired enterprise remains intact as a separate legal
entity. The parent-subsidiary relationship is accounted for as a purchase, and
it is referred to as an acquisition.  Meditecnic,
S.A.originally authorized and issued One
Hundred (100) bearer shares of stock, which were issued to one (1) shareholder.
These stocks were cancelled as part of the acquisition agreement. In an
acquisition the stock disclosures are presented by retroactively stating the
equity accounts as of the earliest period presented to give effect to the new
capital structure subsequent to the acquisition.  No additional shares of stock will be issued as part of
this purchase option agreement. Therefore the equity section of the financial
statements presented reports the total number of shares issued as of December
31, 2005 as Seven Million Five Hundred Twenty Seven Thousand Four Hundred Eighty
Five (7,527,485) shares of common stock.  Meditecnic, SA had assets valued at $420,017; therefore
the Seven Million Five Hundred Twenty Seven Thousand Four Hundred Eighty Five
(7,527,485) share of common stock on shares of Meditecnic, SA Corp still issued
and outstanding had a value of .0558 cents per share at the date of
acquisition.  Meditecnic, Inc. had assets on the books valuing Two Million
six Hundred Twenty Thousand Four Hundred Sixty Three (2,620,463) resulting in a
stock value of .348 cents per share prior to the acquisition.  The acquisition resulted in an increase in the value of
the outstanding Seven Million Five Hundred Twenty Seven Thousand Four Hundred
Eighty Five (7,527,485) shares of common stock to .404 cents per share. 
This resulted in a reverse dilution of .056 cents per share equal to a .161
percent dilution.  Per the purchase option agreement all One Hundred (100)
shares of stock were obtained from Meditecnic, S.A. when the option was
exercised on June 6, 2002.  The Company stock was purchased at fair market
value.  Therefore, these financial statements are presented as if the
acquisition had occurred during the periods presented.  Item
2.            
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
CONDITION  The Company had no sales in the three and nine months ended September 30, 2006
and in the three and nine months ended September 30, 2005. Our net loss was
$104,911 and $368,868 in the  three and nine months ended September 30,
2006, compared to $112,699 and $552,599 for the three and nine months ended
September 30, 2005. The decrease in net loss is the result of cost cutting
measures in payroll, rent, legal,and patent costs offset by increased audit
costs.  The Company
invests cash in marketable securities. A portion of the Companys assets are
valued in currencies other than the US dollar, primarily Swiss francs. We
recognize gains and losses on the currency exchange rate changes from time to
time.  The Company is being funded by shareholder loans and loans from Sonnig,  a
related party. Because of the Companys lack of cash, it is unable to engage in
significant marketing of its products and the Company has no sales. Management
has not determined whether it can obtain loans or equity infusions from persons
other than shareholders or Sonnig, but effective marketing of its products will
likely require in excess of $1 million. In the nine months ended September 30,
2006 shareholders and Sonnig loaned funds to the Company, and the total loans as
of September  30, 2006 are $2,210,673. Because of these loans and other
liabilities of the Company,  it has a negative shareholderss equity. Until
such time as the Company is able to obtain a substantial infusion of cash,
whether from additional loans, bank lines of credit or placements of its
securities, it will be unable to generate sales.  In
the European areas in which we operate the economic stress and the dislocation
of the financial markets that began in late calendar year 2007 has continued and
substantially increased in the recent months. Recently, concerns over inflation,
energy costs, the availability and cost of credit, the conditions of the U.S.
mortgage market and declining real estate prices in the U.S. have contributed to
increased market volatility and diminished expectations about U.S. and the
global economies and the financial markets going forward. These factors,
combined with the volatility in oil prices, declining business and consumer
confidence, and increases in unemployment rates, have precipitated an economic
slowdown and fears of a potential recession on a global scale.  Off
Balance Sheet Obligations and Contractual Obligations  We have no obligations required to be reported under this item. Inflation We believe that inflation currently does not have a
material effect on our results of operations. Critical Accounting Policies and Estimates The preparation of financial statements in conformity
with GAAP requires us to make estimates and assumptions that affect the reported
amounts of assets, liabilities, revenues and expenses and disclosure of
contingent assets and liabilities in the financial statements. Actual results
may differ from these estimates. We believe these estimates and assumptions are
reasonable. We consider accounting policies to be critical when they require us
to make assumptions about matters that are highly uncertain at the time the
accounting estimate is made and when different estimates that our management
reasonably could have used have a material effect on the presentation of our
financial condition, changes in financial condition or results of operations. Our critical accounting policies include but are not
limited to the valuation of inventories and valuation of patents. When necessary, we adjust the carrying value of
inventories to the lower of cost or market, including costs to sell or dispose,
and for estimated inventory shrinkage. Inventories are stated at the lower of
cost (first in, first out method) or market (net realizable value). Estimates of
the future demand for our products, age of the inventory and changes in
stock-keeping units are some of the key factors used by our management in
assessing the net realizable value of inventories. We capitalize our patents and
patent costs as incurred.  The value of our patents must be periodically
reviewed for impairment, and amortized once the patents are
commercialized. Forward
Looking Statements  Information
included in this annual report  includes forward looking statements, which
can be identified by the use of forward-looking terminology such as may, expect,
anticipate, believe, estimate, or continue, or the negative thereof or other
variations thereon or comparable terminology. The statements in "Risk Factors"
and other statements and disclaimers in this registration statement constitute
cautionary statements identifying important factors, including risks and
uncertainties, relating to the forward-looking statements that could cause
actual results to differ materially from those reflected in the forward-looking
statements.  Since
we have not yet generated significant revenues, we are a development stage
company as that term is defined in paragraphs 8 and 9 of SFAS No. 7.
  Our auditors have included an explanatory paragraph in their report
on our financial statements, relating to the uncertainty of our business as a
going concern, due to our lack of operating history or current revenues and
competitive position.  We do not believe that conventional financing, such
as bank loans, is available to us due to these factors.  We have no bank
line of credit available to us.  Management believes that it will be able
to raise the required funds for operations from one or more future offerings, in
order to effect our business plan.  Our
future operating results are subject to many facilities, including:  o
    our success in developing our technology;  o
    our ability to obtain customers for our devices;  o
    the effects of competition;  o
    our ability to obtain additional financing; and  o
    other risks which we identify in future filings with the
SEC.  Any
or all of our forward looking statements in this annual report and in any other
public statement we make may turn out to be wrong. They can be affected by
inaccurate assumptions we might make or by known or unknown risks and
uncertainties. Consequently, no forward looking statement can be guaranteed. In
addition, we undertake no responsibility to update any forward-looking statement
to reflect events or circumstances which occur after the date of this
report.  Item 3.Controls and Procedures.  (a) Evaluation of
disclosure controls and procedures. The Companys principal executive officer
and its principal financial officer, based on their evaluation of the Companys
disclosure controls and procedures (as defined in Exchange Act Rules 13a-14(c)
and 15d -14 (c) as of a date within 90 days prior to the filing of this
Quarterly Report on Form 10QSB, have concluded that the Companys disclosure controls and procedures are adequate
and effective for the purposes set forth in the definition in Exchange Act
rules.  (b) Changes in
internal controls. There were no significant changes in the Companys internal
controls or in other factors that could significantly affect the Companys
internal controls subsequent to the date of their evaluation.  PART II.  OTHER INFORMATION  Item 1. LEGAL PROCEEDINGS  - 
None  Item 2. CHANGES IN SECURITIES -
None  Item 3. DEFAULTS UPON SENIOR SECURITIES -
None  Item 4. SUBMISSION OF MATTERS TO A VOTE OF
SECURITY HOLDERS - None  Item 5. OTHER INFORMATION -
None  Item 6.
EXHIBITS       ---  31       
31.1 Certification of the Chief Executive  Officer pursuant to Rule 13a-14
of the Securities and Exchange  Act of 1934 as amended, as adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2003. Filed herewith. 31.2
Certification of the Chief Financial Officer pursuant to Rule 13a-14 of the
Securities and Exchange Act of 1934 as amended, as adopted pursuant to Section
302 of the Sarbanes-Oxley Act of 2003. Filed herewith.  32        32.1
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2003. Filed
herewith.  32.2Certification of the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2003. Filed herewith.    SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.   MEDITECNIC, INC.    Date:    December 4,
2008                                          
By:/s/ Luc
Badel Luc Badel Treasurer (chief financial officer and accounting officer and duly authorized officer)